Drug Shortage Report for TEGRETOL SUSPENSION
Report ID | 235981 |
Drug Identification Number | 02194333 |
Brand name | TEGRETOL SUSPENSION |
Common or Proper name | TEGRETOL SUSPENSION 100MG/5ML 450 ML |
Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | CARBAMAZEPINE |
Strength(s) | 100MG |
Dosage form(s) | SUSPENSION |
Route of administration | ORAL ORAL |
Packaging size | 450 ML |
ATC code | N03AF |
ATC description | ANTIEPILEPTICS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2024-10-16 |
Actual start date | |
Estimated end date | 2024-10-23 |
Actual end date | |
Shortage status | Anticipated shortage |
Updated date | 2024-10-10 |
Company comments | Product on allocation to minimize patient impact. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2024-10-10 | French | Compare |
v5 | 2024-10-10 | English | Compare |
v4 | 2024-10-02 | English | Compare |
v3 | 2024-08-27 | French | Compare |
v2 | 2024-08-27 | French | Compare |
v1 | 2024-08-27 | English | Compare |
Showing 1 to 6 of 6